TY - JOUR
T1 - A prospective, randomized and blinded comparison between 10,000 IU urinary and 250 μg recombinant human chorionic gonadotropin for oocyte maturation in in vitro fertilization cycles
AU - Abdelmassih, Vicente
AU - Oliveira, Flavio G.
AU - Goncalves, Sergio P.
AU - Varella, Adriana D.
AU - Diamond, Michael P.
AU - Abdelmassih, Roger
N1 - Funding Information:
The authors wish to thank Dr Clovis Sanjar, Serono Inc., São Paulo, Brazil, who was present from our first meeting to discuss this project, and Joan Schertz, Serono Inc., Rockland, MA, USA, for invaluable editing assistance. Supported by a grant from Serono Inc., São Paulo, Brazil.
PY - 2005/4
Y1 - 2005/4
N2 - Purpose: To compare the efficacy and safety of u-hCG with r-hCG in IVF cycles. Methods: A prospective, investigator-blind, randomized, comparative study. Patients (n = 100) ≤35 years with IVF indication were randomly assigned on the day of hCG administration for oocyte maturation to receive either u-hCG (10,000 IU) or r-hCG (250 μ g). Results: No statistical differences were found between groups in relation to total number of oocytes retrieved, percentage of mature oocytes, number of injected oocytes, fertilization rates and number of embryos transferred. The data indicate a possible trend toward a higher incidence of pregnancy in the r-hCG group. Adverse events, predominantly injection-site reactions, were significantly more common in the u-hCG group. Conclusions: r-hCG is at least as effective for inducing final stages of oocyte maturation as 10,000 IU u-hCG and is also associated with significantly better patient tolerance and thus higher patient acceptability.
AB - Purpose: To compare the efficacy and safety of u-hCG with r-hCG in IVF cycles. Methods: A prospective, investigator-blind, randomized, comparative study. Patients (n = 100) ≤35 years with IVF indication were randomly assigned on the day of hCG administration for oocyte maturation to receive either u-hCG (10,000 IU) or r-hCG (250 μ g). Results: No statistical differences were found between groups in relation to total number of oocytes retrieved, percentage of mature oocytes, number of injected oocytes, fertilization rates and number of embryos transferred. The data indicate a possible trend toward a higher incidence of pregnancy in the r-hCG group. Adverse events, predominantly injection-site reactions, were significantly more common in the u-hCG group. Conclusions: r-hCG is at least as effective for inducing final stages of oocyte maturation as 10,000 IU u-hCG and is also associated with significantly better patient tolerance and thus higher patient acceptability.
KW - In vitro fertilization
KW - Luteinizing hormone
KW - Oocyte maturation
KW - Recombinant human chorionic gonadotropin
KW - Urinary human chorionic gonadotropin
UR - http://www.scopus.com/inward/record.url?scp=20844455772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20844455772&partnerID=8YFLogxK
U2 - 10.1007/s10815-005-4911-9
DO - 10.1007/s10815-005-4911-9
M3 - Article
C2 - 16021858
AN - SCOPUS:20844455772
SN - 1058-0468
VL - 22
SP - 149
EP - 153
JO - Journal of Assisted Reproduction and Genetics
JF - Journal of Assisted Reproduction and Genetics
IS - 4
ER -
